As global markets navigate rising inflation pressures and geopolitical uncertainties, the U.S. stock indices have seen mixed performances with large-cap technology optimism tempered by concerns over higher energy costs and Treasury yields. In this environment, identifying high-growth tech stocks involves looking for companies that can effectively leverage innovation in sectors like artificial intelligence to maintain resilience and capitalize on evolving market dynamics.
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS, oncology, and hematology disorders, with a market cap of €228.35 million.
Operations: Oryzon Genomics focuses on the discovery and development of epigenetics-based therapeutics targeting cancer, CNS, oncology, and hematology disorders. The company operates as a clinical-stage biopharmaceutical entity with a market capitalization of €228.35 million.
Oryzon Genomics is making significant strides in the biotech sector, particularly with its innovative LSD1 inhibitor, iadademstat. Recent clinical trials have shown promising results; for instance, in the ALICE-2 trial, iadademstat combined with azacitidine and venetoclax achieved a 100% overall response rate and a 79% complete response rate among newly diagnosed acute myeloid leukemia patients. This performance is underpinned by a robust R&D commitment, evidenced by their increased annual R&D spending which aligns closely with their revenue growth of 58.3%. Moreover, Oryzon’s strategic presentations at major conferences and positive earnings trends suggest potential upward trajectories in both market presence and financial health.
BME:ORY Revenue and Expenses Breakdown as at May 2026
Simply Wall St Growth Rating: ★★★★★★
Overview: Shenzhen SEICHI Technologies Co., Ltd. focuses on the research, development, production, and sale of new display device testing equipment in China with a market capitalization of CN¥34.23 billion.
Operations: SEICHI Technologies specializes in developing and producing innovative testing equipment for new display devices. The company operates primarily within China’s technology sector, leveraging its expertise to drive sales in this niche market.
Shenzhen SEICHI Technologies has demonstrated robust growth with a significant leap in annual revenue, rising by 39.3%, and an impressive earnings increase of 57.3% per year, outpacing the broader Chinese market’s average. This surge is supported by strategic R&D investments which have seen a substantial uptick, aligning closely with its revenue growth trends. The firm recently turned a net loss into a profit, showcasing strong Q1 performance with sales more than doubling to CNY 332.88 million from the previous year and net income hitting CNY 14.55 million, reversing last year’s loss. These financial improvements reflect not only effective cost management but also an enhanced product offering that resonates well within the tech sector’s evolving landscape.
SHSE:688627 Earnings and Revenue Growth as at May 2026
Simply Wall St Growth Rating: ★★★★★☆
Overview: NextVision Stabilized Systems, Ltd. specializes in the development, manufacturing, and marketing of stabilized day and night cameras for ground and aerial vehicles both in Israel and internationally, with a market cap of ₪26.93 billion.
Operations: NextVision Stabilized Systems, Ltd. focuses on producing advanced stabilized cameras for both ground and aerial vehicles across global markets. The company generates revenue through the sale of these specialized camera systems, catering to various sectors requiring high-quality imaging solutions.
NextVision Stabilized Systems has been making significant strides in the tech industry, particularly with a robust increase in earnings by 67.6% over the past year, outstripping its sector’s average growth. This performance is underpinned by a notable rise in R&D spending, which closely correlates with its revenue growth of 26.4% annually, emphasizing the company’s commitment to innovation and development. Recently, NextVision raised its 2026 revenue forecast to $315 million, up by 15% from earlier projections and marking an impressive year-over-year growth of 87%. This upward revision reflects strong demand and strategic expansions in operational capabilities that could set a new trajectory for sustained growth in upcoming years.
TASE:NXSN Earnings and Revenue Growth as at May 2026
Where To Now?
Ready For A Different Approach?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:ORY SHSE:688627 and TASE:NXSN.
